For how we live.
A trial of an anti-inflammatory antibody cut cardiovascular events without changing lipids. A genetic study of 194,418 people found the inflammation marker everyone measures is not itself causal.
Three 2025 reviews of the same drugs reach three answers: a matched cohort finds less cardiovascular disease on biologics, a network meta-analysis flags one drug as raising events, and 43 trials find nothing.
It found rising microbiome diversity and falling inflammatory markers in the fermented-food arm — and no change in its own primary outcome in the high-fibre arm it was compared against.
The trial's own primary outcome — inflammation — was flat. What the new analysis adds is a molecular account of why the fat loss did not translate into the benefits fasting is sold on.
October brought pooled analyses of ginger and of marine omega-3s. Both report significant effects on blood markers. Neither measured whether anyone got healthier.